



**8th Translational Research Conference
Multiple Myeloma**

March 26-28, 2026 – Stockholm, Sweden

Chairpersons : Hartmut Goldschmidt, Martin Kaiser, Suzanne Lentzsch

Thursday, March 26, 2026

08:30–08:40 Welcome by Conference Chairpersons

08:40-09:15 Keynote Lecture

Chair: Suzanne Lentzsch (New York)

08:40-09:10 How I brought translational medicine from bench to bedside Kenneth C. Anderson (Boston)

09:10-09:15 *Discussion*

SESSION I – MGUS

Chair: Martin Kaiser (London)

09:15-09:20 Introduction Martin Kaiser (London)

09:20-09:35 Screening a healthy population for precursors? Sigrun Thorsteinsdottir (Copenhagen)

09:35-09:50 Flowcytometric characterization of MGUS and SMM Albert Orfao (Salamanca)

09:50-10:05 Immune evolution in plasma cell dyscrasias Madhav Dhodapkar (Atlanta)

10:05-10:12 **Selected brief oral communication** Speaker

10:12-10:40 *Panel discussion*

10:40-11:10 Coffee Break

SESSION II – Smouldering myeloma

Chair: Shaji Kumar (Rochester)

11:10-11:15 Introduction Shaji Kumar (Rochester)

11:15-11:30 How to identify high-risk smouldering multiple myeloma? Maria-Victoria Mateos (Salamanca)

11:30-12:00 **DEBATE: To treat or not to treat smouldering multiple myeloma?**

Audience votes

15/07/2025

11:30-11:45 YES

Meletios Dimopoulos (Athens)

11:45-12:00 NO

Martin Kaiser (London)

Audience votes

12:00-12:07 **Selected brief oral communication**

Speaker

12:07-12:35 *Panel discussion*

12:40-14:30 Lunch

13:20-14:20 Possible slot for a satellite symposium

SESSION III – Characterising multiple myeloma

Chair: Albert Orfao (Salamanca)

14:30-14:35 Introduction

Albert Orfao (Salamanca)

14:35-14:50 Molecular drivers of multiple myeloma

Pieter Sonneveld (Rotterdam)

14:50-15:05 Antigen escape in multiple myeloma treatment

Paola Neri (Calgary)

15:05-15:20 Imaging in plasma cell dyscrasias: How, when and how often?

Jens Hillengass (Buffalo)

15:20-15:50 **DEBATE: MRI or PET CT: who is the winner?**

Audience votes

15:20-15:35 MRI

Christina Messiou (Sutton)

15:35-15:50 PET CT

Cristina Nanni (Bologna)*

Audience votes

15:50-15:57 **Selected brief oral communication**

Speaker

15:57-16:25 *Panel discussion*

16:25-16:55 Coffee break

SESSION IV – Newly diagnosed fit multiple myeloma patients

Chair: Philippe Moreau (Nantes)*

16:55-16:50 Introduction

Philippe Moreau (Nantes)*

16:50-17:05 Newly diagnosed multiple myeloma patients

Roberto Mina (Turin)

17:05-17:35 **DEBATE: Transplant vs CAR T cells**

Audience votes

15/07/2025

17:05-17:20	Transplant	Mohammad Mohty (Paris)
17:20-17:35	CAR T Cells	Robert Orlowski (Houston)*
<i>Audience votes</i>		
17:35-17:50	Double vs single standard maintenance	Hartmut Goldschmidt (Heidelberg)
17:50-17:57	Selected brief oral communication	Speaker
17:57-18:25	<i>Panel discussion</i>	
18:30-20:00	Mentored Poster Walks and Welcome Get Together	

Friday, March 27th, 2026

09:00-10:00 Possible slot for a satellite symposium

10:00-10:30 *Coffee break*

SESSION V – Role of frailty for treatment decisions

Chair: Pieter Sonneveld (Rotterdam)

10:30-10:35	Introduction	Pieter Sonneveld (Rotterdam)
10:35-10:50	Who's the frail patient?	Charlotte Pawlyn (London)
10:50-11:05	Is there a limit for induction therapy in multiple myeloma?	Francesca Gay (Turin)
11:05-11:20	Bites or CAR T in frail patients?	Philippe Moreau (Nantes)*
11:20-11:35	MRD driven or QoL driven maintenance in older patients?	Shaji Kumar (Rochester)
11:35-11:42	Selected brief oral communication	Speaker
11:42-12:10	<i>Panel discussion</i>	

12:10-14:05 *Lunch*

12:55-13:55 3 Simultaneous Meet the Expert Sessions

1. Red flags of AL Amyloidosis
2. Pitfalls and tips for an academic career
3. MRD as endpoint in myeloma

Morie Gertz (Rochester)
Paola Neri (Calgary) and
Philippe Moreau (Nantes)*
Luciano Costa (Birmingham, AL)

SESSION VI – Personalising treatment in multiple myeloma

Chair: Marc Raab (Heidelberg)

14:05-14:10	Introduction	Marc Raab (Heidelberg)
-------------	--------------	------------------------

15/07/2025

14:10-14:25	Treatment decision making in high-risk multiple myeloma	Martin Kaiser (London)
14:25-14:40	Management of side effects of CAR Ts and Bispecifics	Noopur Raje (Boston)
14:40-14:55	MRD-directive therapies	Luciano Costa (Birmingham, AL)
14:55-15:10	Precision medicine in multiple myeloma- Future or Reality	Nizar Bahlis (Calgary)
15:10-15:17	Brief Oral Communication	Speaker
15:17-15:45	<i>Panel discussion</i>	
15:45-16:15	<i>Coffee break</i>	

SESSION VII – Relapsed multiple myeloma

Chair: Noopur Raje (Boston)

16:15-16:20	Introduction	Noopur Raje (Boston)
16:20-16:35	When to start treatment to prevent organ damage in relapsed multiple myeloma	Meral Beksac (Istanbul)
16:35-16:50	Sequencing of BCMA treatment	Rakesh Popat (Oxford)
16:50-17:05	When to use GPRC5D targeted treatment	Sham Mailankody (New York)
17:05-17:20	CelMods and combination treatments for relapsed MM	Fredrik Schjesvold (Oslo)
17:20-17:27	Brief Oral Communication	Speaker
17:27-17:55	<i>Panel discussion</i>	
18:05-19:05	Possible slot for a satellite symposium	

Saturday, March 28th 2026

SESSION VIII – Novel technologies for tailored treatment

Chair: Hartmut Goldschmidt (Heidelberg)

08:30-08:35	Introduction	Session Chair
08:35-08:50	Using immune profiling to direct cellular therapies	Leo Rasche (Würzburg)
08:50-09:05	Personalized tumour tracking by mass spectrometry	Elias Mai (Heidelberg)
09:05-09:20	Developing an open-access CAR-T, from discovery to licensing	Krina Patel (Houston)*
09:20-09:35	Role of NK cells in myeloma	Evren Alici (Stockholm)

15/07/2025

09:35-09:50	Trispecifics T-cell and bispecific NK-Cell engagers in myeloma treatment	Marc Raab (Heidelberg)
09:50-09:57	Brief Oral Communication	Speaker
09:57-10:25	<i>Panel discussion</i>	
10:25-10:55	<i>Coffee break</i>	
SESSION IX – Amyloidosis and Waldenstrom’s Disease		
Chair: Martin Kaiser (London)		
10:55-11:00	Introduction	Martin Kaiser (London)
11:00-11:15	Cytogenetics and risk assessment in AL Amyloidosis	Stefan Schoenland (Heidelberg)
11:15-11:30	Targeted treatment in relapsed AL amyloidosis	Rajshekhar Chakraborty (New York)
11:30-11:45	Immunotherapy as Anti-Amyloid Strategies	Suzanne Lentzsch (New York)
11:45-12:00	Latest approaches to treat Waldenstrom's disease	Morie Gertz (Rochester)
12:00-12:07	Brief Oral Communication	Speaker
12:07-12:35	<i>Panel discussion</i>	
12:35-12:45	<i>Closing Remarks</i>	

MEETING CLOSURE

**Pending confirmation*